
His route from Michigan engineering classrooms to a $130 million clinical-stage company is a study in useful detours, patient capital and the discipline to stop doing everything at once.

The XLSCOUT CEO learned intellectual property from the transaction side - engineering, technology transfer, licensing and acquisition. Now he is betting that patent-trained AI can make difficult work faster without pretending the domain is simple.